NCT06225635View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

March 7, 2022

Study Completion Date

March 7, 2022

Conditions
Hyperlipidemias
Interventions
DRUG

Ezerosu(monolayer tablet)

Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)

DRUG

Ezerosu(double layer tablet)

Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)

Trial Locations (1)

Unknown

H Plus Yangji Hospital, Seoul

All Listed Sponsors
lead

Shin Poong Pharmaceutical Co. Ltd.

INDUSTRY

NCT06225635 - A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab | Biotech Hunter | Biotech Hunter